# Ruijiming Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruijiming-biological

- Industry: Materials
- Headquarters: Yantai, China
- Website: www.mgpdrn.cn/
- Total disclosed funding: $2.5M
- Latest round: Series B (Apr 13, 2026)
- Investors on record: 3

## About

Founded in 2020 and based in Yantai, China, Ruijiming (Shandong) Biotechnology Co., Ltd., trading as Ruijiming Biological, operates as a biomaterial company that focuses on the production and sales of marine bioactive substances and bio-based materials. It was recognized as the National High-tech Enterprise. The company acquired the national ISO9001 system certification. It has 21 patents and 1 software copyright. In April 2026, Ruijiming Biological raised CNY 17 million in series B funding from Chuchang Fund.

Ruijiming Biological is mainly engaged in the research, development, production, and sales of regenerative medicine aesthetic raw materials, marine bioactive substances, and bio-based materials. The company has multiple GMP-grade large-scale production lines for nucleic acid raw materials. Its core products are medical and cosmetic grade marine biological raw materials - PDRN (polydeoxyribonucleotide) and PN (polynucleotide).

The company generates revenue by selling marine bioactive substances and bio-based materials.

The company will use the latest funding for its layout in raw material research and development, production and market expansion.

## Funding rounds

- Series B, Apr 13, 2026, $2.5M — Chuchang Fund
- Series A, Jul 20, 2024 — Yujiahui, Huiyu Private Equity Fund Management (Huzhou)

## Investors

- Yujiahui — Series A
- Huiyu Private Equity Fund Management (Huzhou) (https://capitalatlas.ai/funds/huiyu-private-equity-fund-management-huzhou) — Series A
- Chuchang Fund (https://capitalatlas.ai/funds/chuchang-fund) — Series B